{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Adverse events by grade will be summarized. The occurrence of grade 3+ adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) will be summarized as well. Adverse events will initially be reviewed regardless of attribution, but also according to whether adverse events are possibly, probably, or definitely related to treatment.","groups":[{"description":"Patients receive fludarabine IV on days -5 to -2 and melphalan IV on days -3 to -2, then undergo stem cell transplantation on day 0. Patients receive cyclophosphamide on days 3 and 4, tacrolimus PO BID or IV starting on day 5, and mycophenolate mofetil IV or PO TID on days 5 to 35. Patients also receive daratumumab IV starting between days 90-150 for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic stem cell transplantation\n\nCyclophosphamide: Given IV\n\nDaratumumab: Given IV\n\nFludarabine: Given IV\n\nMelphalan: Given IV\n\nMycophenolate Mofetil: Given IV or PO\n\nTacrolimus: Given PO or IV","id":"OG000","title":"Treatment (Conditioning Regimen, Stem Cell Transplant)"}],"populationDescription":"Data was unable to be collected and analyzed due to low patient accrual to study","reportingStatus":"POSTED","timeFrame":"Up to 2 years post-transplant","title":"Incidence of Adverse Events","type":"SECONDARY"}